{
    "Trade/Device Name(s)": [
        "Access Thyroglobulin Antibody II"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K213517",
    "Predicate Device Reference 510(k) Number(s)": [
        "K112933"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JZO"
    ],
    "Summary Letter Date": "September 26, 2023",
    "Summary Letter Received Date": "March 10, 2023",
    "Submission Date": "September 22, 2023",
    "Regulation Number(s)": [
        "21 CFR 866.5870"
    ],
    "Regulation Name(s)": [
        "Thyroid Autoantibody Immunological Test System"
    ],
    "Analyte Class(es)": [
        "autoimmune",
        "immunology"
    ],
    "Analyte(s)": [
        "Thyroglobulin antibody"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Lithium heparin tube",
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Access Immunoassay Systems",
        "Access 2 Immunoassay Analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay",
        "Sandwich immunoassay",
        "Automated immunoassay"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for Access Thyroglobulin Antibody II chemiluminescent immunoassay for quantitative measurement of thyroglobulin antibody in serum and plasma.",
    "Indications for Use Summary": "Quantitative determination of thyroglobulin antibody in human serum and plasma to aid in the diagnosis of Hashimoto's disease, nontoxic goiter, and Graves' disease.",
    "fda_folder": "Immunology"
}